Toward the Use of Nanopore RNA Sequencing Technologies in the Clinic: Challenges and Opportunities

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2025 Mar 8

PMID 40057374

Authors

Xanthi-Lida Katopodi

Oguzhan Begik

Eva Maria Novoa

Affiliations

Soon will be listed here.

Abstract

RNA molecules have garnered increased attention as potential clinical biomarkers in recent years. While short-read sequencing and quantitative polymerase chain reaction have been the primary methods for quantifying RNA abundance, they typically fail to capture critical post-transcriptional regulatory elements, such as RNA modifications, which are often dysregulated in disease contexts. A promising cutting-edge technique sequencing method that addresses this gap is direct RNA sequencing, offered by Oxford Nanopore Technologies, which can simultaneously capture both RNA abundance and modification information. The rapid advancements in this platform, along with growing evidence of dysregulated RNA species in biofluids, presents a compelling clinical opportunity. In this review, we discuss the challenges and the emerging opportunities for the adoption of nanopore RNA sequencing technologies in the clinic, highlighting their potential to revolutionize personalized medicine and disease monitoring.

References

Jia J, Yang S, Huang J, Zheng H, He Y, Wang L . Distinct Extracellular RNA Profiles in Different Plasma Components. Front Genet. 2021; 12:564780. PMC: 8256274. DOI: 10.3389/fgene.2021.564780. View

Schwartz S, Motorin Y . Next-generation sequencing technologies for detection of modified nucleotides in RNAs. RNA Biol. 2016; 14(9):1124-1137. PMC: 5699547. DOI: 10.1080/15476286.2016.1251543. View

Wurdinger T, In t Veld S, Best M . Platelet RNA as Pan-Tumor Biomarker for Cancer Detection. Cancer Res. 2020; 80(7):1371-1373. DOI: 10.1158/0008-5472.CAN-19-3684. View

Acera Mateos P, J Sethi A, Ravindran A, Srivastava A, Woodward K, Mahmud S . Prediction of m6A and m5C at single-molecule resolution reveals a transcriptome-wide co-occurrence of RNA modifications. Nat Commun. 2024; 15(1):3899. PMC: 11082244. DOI: 10.1038/s41467-024-47953-7. View

Reggiardo R, Maroli S, Peddu V, Davidson A, Hill A, LaMontagne E . Profiling of repetitive RNA sequences in the blood plasma of patients with cancer. Nat Biomed Eng. 2023; 7(12):1627-1635. PMC: 10727983. DOI: 10.1038/s41551-023-01081-7. View

Byron S, Van Keuren-Jensen K, Engelthaler D, Carpten J, Craig D . Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17(5):257-71. PMC: 7097555. DOI: 10.1038/nrg.2016.10. View

Cruciani S, Delgado-Tejedor A, Pryszcz L, Medina R, Llovera L, Novoa E . De novo basecalling of RNA modifications at single molecule and nucleotide resolution. Genome Biol. 2025; 26(1):38. PMC: 11853310. DOI: 10.1186/s13059-025-03498-6. View

Zheng Z, Pang C, Yang Y, Duan Q, Zhang J, Liu W . Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res. 2017; 46(1):348-356. PMC: 6011314. DOI: 10.1177/0300060517726441. View

Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D . The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017; 551(7679):251-255. DOI: 10.1038/nature24456. View

10.

Munro R, Santos R, Payne A, Forey T, Osei S, Holmes N . minoTour, real-time monitoring and analysis for nanopore sequencers. Bioinformatics. 2021; 38(4):1133-1135. PMC: 8796371. DOI: 10.1093/bioinformatics/btab780. View

11.

Workman R, Tang A, Tang P, Jain M, Tyson J, Razaghi R . Nanopore native RNA sequencing of a human poly(A) transcriptome. Nat Methods. 2019; 16(12):1297-1305. PMC: 7768885. DOI: 10.1038/s41592-019-0617-2. View

12.

Motorin Y, Muller S, Behm-Ansmant I, Branlant C . Identification of modified residues in RNAs by reverse transcription-based methods. Methods Enzymol. 2007; 425:21-53. DOI: 10.1016/S0076-6879(07)25002-5. View

13.

Anastassiadis T, Kohrer C . Ushering in the era of tRNA medicines. J Biol Chem. 2023; 299(10):105246. PMC: 10583094. DOI: 10.1016/j.jbc.2023.105246. View

14.

Garalde D, Snell E, Jachimowicz D, Sipos B, Lloyd J, Bruce M . Highly parallel direct RNA sequencing on an array of nanopores. Nat Methods. 2018; 15(3):201-206. DOI: 10.1038/nmeth.4577. View

15.

Lan H, Lu H, Wang X, Jin H . MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015; 2015:125094. PMC: 4385606. DOI: 10.1155/2015/125094. View

16.

Zheng G, Qin Y, Clark W, Dai Q, Yi C, He C . Efficient and quantitative high-throughput tRNA sequencing. Nat Methods. 2015; 12(9):835-837. PMC: 4624326. DOI: 10.1038/nmeth.3478. View

17.

Schwartz S, Bernstein D, Mumbach M, Jovanovic M, Herbst R, Leon-Ricardo B . Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell. 2014; 159(1):148-162. PMC: 4180118. DOI: 10.1016/j.cell.2014.08.028. View

18.

Fish L, Zhang S, Yu J, Culbertson B, Zhou A, Goga A . Cancer cells exploit an orphan RNA to drive metastatic progression. Nat Med. 2018; 24(11):1743-1751. PMC: 6223318. DOI: 10.1038/s41591-018-0230-4. View

19.

Dhahbi J, Spindler S, Atamna H, Boffelli D, Martin D . Deep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer. Biomark Cancer. 2014; 6:37-47. PMC: 4260766. DOI: 10.4137/BIC.S20764. View

20.

. Exploring tRNAs and their modifications and crosstalk using Nano-tRNAseq. Nat Biotechnol. 2023; 42(1):38-39. DOI: 10.1038/s41587-023-01755-2. View